A groundbreaking medical feat has been achieved: a gene-edited pig liver has been successfully transplanted into a living human, marking a world-first! This incredible procedure offers a glimpse into the future of medicine, but it also highlights significant challenges. Let's dive in.
Chinese surgeons made history by using a 10-gene-edited pig liver as an auxiliary graft in a 71-year-old man. This means the pig liver was used to support the patient's own liver, rather than completely replacing it. The patient was suffering from hepatitis B-related cirrhosis and a massive, inoperable hepatocellular carcinoma (liver cancer). With the patient's condition rapidly deteriorating and no human liver donors available, the medical team made the bold decision to proceed with this experimental procedure on May 17, 2024, under compassionate use.
So, how did they engineer this pig liver? The donor pig, a Diannan miniature pig, underwent 10 precise genetic modifications. These modifications involved knocking out key genes that would cause the human body to reject the pig liver (xenoantigens). Additionally, seven human genes were inserted to improve immune and coagulation compatibility. This complex genetic editing was crucial to the success of the transplant. Immediately after the procedure, the graft started producing bile and contributing to the patient's metabolism, bile acid synthesis, albumin production, and coagulation factor generation. Early results showed stable liver and kidney function, with no signs of rejection.
But here's where it gets controversial... Unfortunately, about a month after the surgery, the patient developed xenotransplantation-associated thrombotic microangiopathy (xTMA). This serious condition led to hemolysis, thrombocytopenia, complement activation, and microvascular thrombosis. Despite aggressive treatment, the pig graft had to be removed on day 38. The patient's native liver, which had grown larger, was able to maintain sufficient function. While the xTMA resolved, the patient later experienced recurrent bleeding and, sadly, passed away on postoperative day 171.
Investigators concluded that this auxiliary pig-to-human liver xenotransplantation is technically feasible and can provide meaningful support. However, xTMA, coagulation incompatibility, and complement activation remain major obstacles. This case serves as a critical benchmark for future trials. It underscores the urgent need for further gene editing, improved immunosuppression, and targeted strategies to prevent xTMA if xenotransplantation is to become a more widespread treatment option. The study suggests that with further research, xenotransplantation could be a viable option for patients with end-stage liver disease.
What are your thoughts on this groundbreaking procedure? Do you think the potential benefits outweigh the risks? Share your opinions in the comments below!
